Abstract

Obese women are at increased risk of death from cervical cancer compared to non-obese women. Yet, research indicates a lower rate of cervical cancer screening among obese women, especially severely obese white women. Cited reasons for delaying screening include embarrassment, perceived weight stigma, lack of appropriately sized examination equipment and poor patient-provider communication. Parental acceptance of the Human Papillomavirus (HPV) vaccine for overweight adolescent females may decrease the incidence of cervical cancer among obese women in later years. This study seeks to determine the Human Papillomavirus (HPV) vaccination status of females, ages 11 to 21 years, in a university-based pediatric practice and to determine the correlation between HPV vaccine status and body mass index (BMI). Methods: We reviewed 800 randomly selected paper medical charts of females, ages 11 to 21 years, enrolled in a university-based pediatric practice as of October 31, 2008. Data collected included age, height, weight, BMI, race, insurance carrier, immunizations, sexually transmitted infections (STIs) and documentation of STI prevention counseling. Statistical analysis was performed to determine associations among risk factors and outcome variables. Results: 800 charts reviewed; 91 were incomplete due to missing documentation of immunizations. The remaining 709 charts included 338 (48.2%) African Americans; 302 (43.1%) Whites; 26 (3.7%) Hispanics; and 35 (5%) other. Approximately 28.2% had current HPV vaccine status. There was no correlation between HPV vaccination status and BMI (p >0.05).

Highlights

  • There was no correlation between Human Papillomavirus (HPV) vaccination status and body mass index (BMI) (p >0.05)

  • High school students with extreme obesity participate in risk-taking behavior similar to healthy weight peers [1]

  • Parental concern that HPV vaccine may lead to promiscuity has not been substantiated [3], HPV vaccination rates among adolescents remain low

Read more

Summary

Methods

We reviewed 800 randomly selected paper medical charts of females, ages 11 to 21 years, enrolled in a university-based pediatric practice as of October 31, 2008. The pediatric outpatient practice enrolled patients from birth until age 21 year and the study population is representative of the Lucas County population based on the 2009 census. The University of Toledo outpatient pediatric practice recommends the HPV vaccine at age 11 years. Medicaid covers the HPV vaccine for ages 9 thru 18 years and the commercial insurers cover the vaccine for ages 9 thru years or ages 8 thru years. After approval by the University of Toledo Institutional Review Board (IRB) the study was started as the scholarly project by one of the authors who was a third year pediatric resident (EM) and her faculty mentor (JRG). The other author (HD) was contracted as the statistician and has collaborated with JRG on previous research studies

Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call